AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05318040
Drug: CMS121
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMS121 is a small molecule to be delivered orally in capsule form and is a therapeutic drug candidate for treatment of Alzheimer's Disease
Trial: NCT04340908
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo tablet, oral, once daily, 1-year treatment, postoperation
Trial: NCT05376904
Drug: HR18034
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR18034 low dose
Trial: NCT05376904
Drug: HR18034
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR18034 midium dose
Trial: NCT05376904
Drug: HR18034
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HR18034 high dose
Trial: NCT05318040
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be provided as visually matching placebo capsules.
Trial: NCT06376981
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An injection of 1 ml of corticosteroids
Trial: NCT06376981
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An injection of 2 ml of placebo (physiological serum)
Trial: NCT05837299
Drug: IMC008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: allowing 10% dose error
Trial: NCT04161599
Drug: Sodium picosulfate, light magnesium oxide, anhydrous citric acid 10 mg/3.5 g/10.97 g Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laxative for bowel cleansing
Trial: NCT04684641
Drug: Standard Dose YPT-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive the standard dose of phage therapy YPT-01.
Trial: NCT06244121
Drug: Pyridoxine
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pyridoxine (Vitamin B6) will be given as an anti oxidant.
Trial: NCT06244121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given in control group
Trial: NCT05847322
Drug: Azithromycin Pill
RxNorm normalized name: azithromycin Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 3 day course of azithromycin will be administered to all colonised volunteers at week 6, or sooner if early pertussis disease is suspected
Trial: NCT03529448
Drug: TN-TC11G
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TN-TC11G dose will be gradually increased as follows:~Week 1: TN-TC11G: 0-0-5 mg (THC 5 mg + CBD 5 mg; in the mornings, 90 minutes after breakfast; in the afternoons, 90 minutes after lunch; in the evenings, 90 minutes after dinner).~Week 2: TN-TC11G: 5-0-5 mg Week 3: TN-TC11G: 5-5-5 mg Week 4: TN-TC11G: 5-5-10 mg Week 5: TN-TC11G: 5-5-15 mg Week 6: TN-TC11G: 10-10-15 mg Week 7: TN-TC11G: 10-10-20 mg. Week 8: TN-TC11G: 15-15-30 mg Week 9: TN-TC11G: 20-20-40 mg TN-TC11G will be administered daily at the relevant dose level according to the individual titration performed in the first 9 weeks of treatment. If there is any dose reduction, the reduced dose must be administered.
Trial: NCT04749355
Drug: BST-236
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BST-236 is a conjugate of cytarabine and asparagine, provided as a sterile lyophilized powder for IV administration
Trial: NCT04719663
Drug: Active pharmacological placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active placebo pill does not have direct effects on the brain. Buscopan (butylscopolamine, 10 mg daily, 1 pill in the morning) does not cross the blood-brain barrier, yet induces some smaller side effects that resemble those of antidepressants (e.g., mouth dryness, fatigue, nausea). Treatment duration is 4 weeks. The rationale is briefly explained to participants as stimulating the biological balance in humans with depression, using a well-tolerated drug similar to Buscopan, which is well-known from pain treatments.
Trial: NCT04931459
Drug: ACU193
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ACU193
Trial: NCT04931459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Placebo
Trial: NCT05188131
Drug: Intravenous Infusion of Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Infusion of Diclofenac Sodium is administered at the dose of 75 mg, diluted in 100 ml of isotonic saline, over 15 minutes.
Trial: NCT05188131
Drug: Intravenous Infusion of Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Infusion of Placebo (represented by 100 ml of isotonic saline) is administered over 15 minutes.
Trial: NCT04665609
Drug: TQB2450 solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 solution is a new novel of PD-L1 inhibitor made by Crown Bioscience and CHIATAI TIANQING(CTTQ PHARMA).
Trial: NCT05034536
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT05419947
Drug: VERDYE powder for solution for injection 25 mg
RxNorm normalized name: palo verde pollen extract Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verdye 25 mg contains sodium VI powder for solution for injection. VI is a water-soluble agent with a spectral absorption peak of 800 nm. It is a drug approved for diagnostic use only and is indicated for the measurement of the excretory function of the liver.
Trial: NCT05147337
Drug: E2511
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: E2511 tablets.
Trial: NCT05147337
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2511 matched placebo tablets.
Trial: NCT04707131
Drug: LEM-S401
FDA approved: no
EMA approved: no
PMDA approved: no
Description: siRNA encapsulated in DegradaBALL®
Trial: NCT04707131
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05332678
Drug: SLS-005 - Once Weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Please see Arm description.
Trial: NCT05332678
Drug: SLS-005 - Twice Weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Please see Arm description.
Trial: NCT06205641
Drug: Xuanfei Baidu Granule Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take Xuanfei Baidu Granule Placebo 1 bag in the morning and evening with boiling water for 5 days.
Trial: NCT06205641
Drug: Xuanfei Baidu Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take Xuanfei Baidu Granule 1 bag in the morning and evening with boiling water for 5 days.
Trial: NCT05471440
Drug: Direct boost mRNA
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be boosted with a covid-19 vaccin after priming with mRNA
Trial: NCT05471440
Drug: Direct boost adeno
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be boosted with a covid-19 vaccin after priming with adeno
Trial: NCT06019065
Drug: AJA001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AJA001
Trial: NCT05005299
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is administered as an intravenous infusion at a dose of 750mg/m2 daily, to be administered over 30 minutes and to commence 1 hour after fludarabine infusion.
Trial: NCT04855292
Drug: TG103 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TG103 injection, SC, once weekly
Trial: NCT04855292
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control, SC, once weekly
Trial: NCT05495698
Drug: single-inhaler triple therapy (Trimbow)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the intervention group will receive the triple therapy in one inhaler in stead of multiple inhalers. The actual medication is the same.
Trial: NCT05495698
Drug: multi-inhaler triple therapy (Qvar + Bevespi)
RxNorm normalized name: Bevespi Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the intervention group will receive the triple therapy in multiple inhalers. The actual medication is the same.
Trial: NCT05269537
Drug: Intrathecal Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 15 μg will be administered in the subarachnoid space
Trial: NCT05269537
Drug: Crystalloid Coload 1000 mL
RxNorm normalized name: influenza B virus B/Colorado/06/2017 antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer acetate 1000 mL will be administered over 10 minutes starting immediately after intrathecal injection
Trial: NCT06212089
Drug: TR-012001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of TR-012001 will be administered.
Trial: NCT05176691
Drug: HMPL-760
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally QD for 28-day cycles
Trial: NCT05167084
Drug: Placebo 250 mg Tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During another phase of the study: identical looking placebo pills starting Day 1 0-1-1, day 2 1-2-2, day 3 2-2-3 day 4 3-3-4 day 5 3-3-4 day 6 3-3-4 day 7 3-3-4 day 8 3-0-0
Trial: NCT05355129
Drug: TT-00920 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT04670770
Drug: Drug - SHR1459
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablets taken once daily for 52 weeks
Trial: NCT05068947
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT06378697
Drug: Placebo+AK111
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo+AK111 placebo subcutaneous injection at week 0,1, 4,8 and 12 follow AK111 4-weekly thereafter until week 48.
Trial: NCT00373919
Drug: intravenous (IV) administration of erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05068921
Drug: TQB2858 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2858 is an anti-programmed death ligand 1（PD-L1）/transforming growth factor-β （TGF-β） bi-functional fusion protein.
Trial: NCT05921071
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive 10 ml of normal saline 0.9% intravenously.
Trial: NCT06241196
Drug: Alloderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: allogenic soft tissue substitute
Trial: NCT06241196
Drug: Xenogenic bone membrane shield
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xenogenic bone membrane
Trial: NCT05509543
Drug: IY-NT-R
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilaprazole 10mg
Trial: NCT04920747
Drug: Taxane
RxNorm normalized name: Taxanes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: docetaxel or paclitaxel
Trial: NCT04698915
Drug: Drug GC4711
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 Minute IV Infusion
Trial: NCT04698915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 Minute IV Infusion
Trial: NCT05492968
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the norepinephrine group will receive a continuous infusion containing norepinephrine with a concentration of 0.02mg/ml for intraoperative blood pressure management. The infusion will be started with 0.15mL/kg/h and will be titrated to receive a mean arterial pressure of at least 75mmHg.
Trial: NCT05749861
Drug: CKD-828, D097, D337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT05282251
Drug: Intravenous paracetamol and ketorolac
RxNorm normalized name: phenylephrine and ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous analgesia: paracetamol (one gram) and Ketorolac (30 mg) + Intrapleural normal saline (10 ml) as a placebo
Trial: NCT05194163
Drug: MW150
RxNorm normalized name: Minocycline hydrochloride
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral-delivered capsule of study drug
Trial: NCT05194163
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral delivered capsule matched to study drug capsule
Trial: NCT05625347
Drug: single dose (162 mg) of non-enteric-coated chewable aspirin tablets
RxNorm normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: orally administered
Trial: NCT05399368
Drug: RPT193
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPT193 is an antagonist of the C-C motif chemokine receptor 4 (CCR4) that inhibits CCR4-mediated chemotaxis toward both CCL22 and CCL17
Trial: NCT04825860
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
Trial: NCT06333977
Drug: LC542019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dose, once daily
Trial: NCT06333977
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT05974683
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue use of current basic maintenance treatment of IgG4-RD plus placebo, Follow-up intervals: week 4, week 12, week 24, week 36, week 52
Trial: NCT05476510
Drug: Postoperative management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered ibuprofen 400 mgr IV every 8 hours in the postoperative period. Postoperative patient evaluation will be performed by a pain nurse blinded to the procedure. 100 mg tramadol will be performed for rescue analgesia.
Trial: NCT05638347
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral administration
Trial: NCT06520891
Drug: Statin and SGLT2i
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin as atrovastatin SGLT2i as dapagliflozin
Trial: NCT05393089
Drug: AGN-190584
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drops
Trial: NCT05393089
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye drops
Trial: NCT06485336
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each tablet will be taken once daily for 84 days.
Trial: NCT05245591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 100 mg three times daily (tid) for 0-8 weeks Placebo 100 mg twice daily (bid) for 9-16 weeks
Trial: NCT05205109
Drug: KEYTRUDA ®( Pembrolizumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part I: After 2 cycles of ATG-037 monotherapy, eligible participants will receive ATG-037 combination therapy with Keytruda ®(Pembrolizumab) 200mg/Q3W fixed dose for up to 35 administrations (approximately 2 years).~Part II: Keytruda ®(Pembrolizumab) will be administered from C1.
Trial: NCT05203705
Drug: SHR2285 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR2285 tablet; dose 1, for 12 days
Trial: NCT05203705
Drug: SHR2285 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR2285 tablet; dose 4, for 12 days
Trial: NCT04831047
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop of placebo (balanced saline solution) will be applied to the ocular surface of each eye.
Trial: NCT05857579
Drug: Home-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based therapy was based on Therapearl eye mask warming compress (Bausch \& Lomb, Madrid, Spain) twice a day and Eyestil synfo eyedrops (Sifi Iberica SL, Madrid, Spain) 4 times a day during the study
Trial: NCT04867785
Drug: LY3437943
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04867785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05789576
Drug: VTAMA (tapinarof) cream, 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VTAMA (tapinarof) cream, 1% applied topically once daily
Trial: NCT05678283
Drug: [14C]CC-90010
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT04312932
Drug: LCPUFA Oil Supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
Trial: NCT06359600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05653271
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lymphodepleting agent
Trial: NCT04744181
Drug: B vitamin
RxNorm normalized name: B-50 Hi Potency B Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of a single dose of B vitamin in those patietns who fulfill the inclusion criteria
Trial: NCT04744181
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration of a single dose of folic acid in those patietns who fulfill the inclusion criteria
Trial: NCT05656443
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04994704
Drug: Propfol group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propfol group will be started and maintained total intravenous anesthesia with propofol and remifentanil under target controlled infusion (TCI) model.
Trial: NCT06514976
Drug: Cytoflavin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin solution for infusions. 20-40 ml/day (10 ml with the interval of 8-12 hours for 10 days; the single dose is increased up to 20 ml in case of the severe form of the disease) by intravenous drop infusion in dilution per 100-200 ml of 0.9% sodium chloride solution for 10 days; rate of administration: 3-4 ml/min
Trial: NCT04848662
Drug: BDA MDI (PT027) 160/180 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/90 μg per puff. Two puffs to administer 160/180 μg dose.
Trial: NCT04848662
Drug: Pulmicort Respules 0.5 MG/ML Inhalation Suspension
RxNorm normalized name: Pulmicort Respules 0.5 MG/ML Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 0.5 mg/ml. Each 2 ml Respule contains 1 mg budesonide.
Trial: NCT04796675
Drug: Fludarabine + Cyclophosphamide + CAR-NK-CD19 Cells
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CAR-NK-CD19 Cells on day 0.
Trial: NCT04930328
Drug: Oxbryta® (voxelotor) 500-mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will have received treatment with Oxbryta as prescribed by their physician at the approved dose per local prescribing information, as part of their usual care.
Trial: NCT05736419
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered Post-Transplant
Trial: NCT06085053
Drug: TQA3038 injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQA3038 is an injection.
Trial: NCT06085053
Drug: TQA3038 injection matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection contains no active substance.
Trial: NCT00513201
Drug: regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05478382
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients are given 0 to 3 capsules per administration according to their allocated group.
Trial: NCT05372887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
Trial: NCT05317507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05280197
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAP block using normal saline
Trial: NCT05952947
Drug: Fludarabine + Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine: 25mg/m²/day×3days; Cyclophosphamide: 250mg/m²/day×3 days
Trial: NCT05321706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized in a 1:1 fashion to receive a matching placebo once daily for one year.
Trial: NCT06121518
Drug: D064 and D702, QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental Group Subjects assigned to this group are treated with D064, D702
Trial: NCT06121518
Drug: D064 and Placebo of D702, QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator Group Subjects assigned to this group are treated with D064, placebo of D702
Trial: NCT06121518
Drug: Placebo of D064 and D702, QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparator Group Subjects assigned to this group are treated with D702, placebo of D064
Trial: NCT04781647
Drug: ABI-H0731
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive ABI-H0731 300 mg tablets orally once daily
Trial: NCT05196971
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 sprays of placebo self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase